Navigation Links
More evidence on benefits of high blood pressure drugs in diabetic eye disease
Date:1/6/2010

Scientists in Massachusetts are reporting new evidence that certain high blood pressure drugs may be useful in preventing and treating diabetic retinopathy, the leading cause of vision loss in people with diabetes. The study, the largest to date on proteins in the retina, could lead to new ways to prevent or treat the sight-threatening disease, they say. The findings are in ACS' Journal of Proteome Research, a monthly publication.

Edward Feener and colleagues point out that diabetic retinopathy is a common complication of diabetes, which affects millions of people worldwide. It involves damage to blood vessels in the retina, the light sensitive tissue in the back of the eye. Previous studies suggested that drugs used to treat high blood pressure, including ACE inhibitors and angiotensin receptor blockers (ARBs), may help prevent the condition.

The scientists analyzed proteins from the retinas laboratory mice with normal blood pressure and diabetes and compared them to those of non-diabetic mice. They identified 65 abnormal proteins in the diabetic mice out of more than 1,700 proteins in the study. Treatment with the ARB medication, candesartan, prevented the abnormal changes in more than 70 percent of the proteins.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert  

Page: 1

Related biology news :

1. A private bandwidth for communication in bats: Evidence from insular horseshoe bats
2. Comet probes reveal evidence of origin of life, scientists claim
3. Evidence of a relationship between swimming babies and infections
4. Researchers find evidence linking stress caused by the Sept. 11 disaster with low birth weights
5. Fossil record supports evidence of impending mass extinction
6. New evidence for female control in reproduction
7. RAND study finds evidence disease management programs
8. CWRU School of Medicine has evidence vaccine against malaria will reduce disease
9. There is powerful evidence of evolution in human DNA
10. Scientific evidence supporting evolution continues to grow
11. No convincing evidence for decline in tropical forests
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
More evidence on benefits of high blood pressure drugs in diabetic eye disease
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has announced ... Home Button Synaptics Fingerprint Sensor Technology Analysis" report ... Based on a totally different sensing ... first time a fingerprint sensor in its product. ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" report ... One major trend upcoming in this ... biomedical applications. Chemical sensors help in recording of patient ...
(Date:12/11/2014)... Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... addition of the "Biometrics Market in India 2015-2019" ... major trend emerging in this market is the adoption ... than one characteristic of an individual for verification and ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... is a newly discovered life history among the 28,300 species ... from arid southwestern Madagascar spends up to three-quarters of its ... is a mere 4 to 5 months. No other known ... a short life span. The new research is reported in ...
... Mary Estes of Baylor College of Medicine and her ... toxic protein that affects the intestines, causing diarrhea. ... receptor on intestinal cells through which the enterotoxin interacts ... the receptor might not be straightforward," said the professor ...
... factors associated with Crohn,s disease have been discovered, ... about the disease. An international consortium of Crohn,s ... Canadian researchers Dr. John D. Rioux from ... Drs. Mark Silverberg and Hillary Steinhart from Mount ...
Cached Biology News:Unheard of life history for a vertebrate 2Integrins as receptors give insight into rotavirus and diarrhea 2Montreal Heart Institute and Mount Sinai Hospital researchers contribute to Crohn's disease study 2
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 Earlier this ... L. Sherley, director of the Adult Stem Cell Technology Center, ... and under appreciated unique property of adult tissue stem cells. ... in the Past, Important for the Future,” embodied the essence ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application and ... manufacturing process, and product cost structure. Production is ... also covers upstream raw materials, equipment, downstream client ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 4, 2011 Advanced Life Sciences Holdings, Inc. ... biopharmaceutical company engaged in the discovery, development and commercialization ... oncology and respiratory diseases, today announced that it will ... held January 10-12th in San Francisco. ...
... 2011 Neogen Corporation (Nasdaq: NEOG ) announced ... FY 2011, which ended Nov. 30, increased 33% from the ... to $6,110,000, or $0.26 per share, compared to the prior ... $43,931,000, compared to the prior year,s $35,251,000. Year-to-date revenues for ...
... Inc. announced today that it has received clearance from ... to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ... solid tumors. (Logo: http://photos.prnewswire.com/prnh/20101101/NY92716LOGO ) ... the activity of semaphorin 4D (SEMA4D).  It is the ...
Cached Biology Technology:Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference 2Neogen Reports 33% Increase in Net Income 2Neogen Reports 33% Increase in Net Income 3Neogen Reports 33% Increase in Net Income 4Neogen Reports 33% Increase in Net Income 5Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors 2
Incomplete Adjuvant...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Biology Products: